Pfizer’s generic deals don’t violate competition law, says Australian court
A court has rejected an appeal by the Australian Competition and Consumer Commission (ACCC), in a decision which confirmed that deals made by Pfizer in relation to generic cholesterol-lowering medication do not constitute a misuse of its market power.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
26 June 2018 The Australian Competition and Consumer Commission said yesterday that it has sought to appeal against a decision by the Full Federal Court of Australia in a case involving Pfizer.
26 June 2018 The Australian Competition and Consumer Commission said yesterday that it has sought to appeal against a decision by the Full Federal Court of Australia in a case involving Pfizer.
26 June 2018 The Australian Competition and Consumer Commission said yesterday that it has sought to appeal against a decision by the Full Federal Court of Australia in a case involving Pfizer.